Humanin

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Humanin?

Humanin is a 24-amino acid peptide encoded within the mitochondrial genome — one of only a small number of known mitochondrial-derived peptides (MDPs). First identified in 2001 from a cDNA library screen of surviving neurons in Alzheimer’s disease brain tissue, humanin was notable as the first open reading frame within mitochondrial 16S rRNA shown to produce a functional peptide with cytoprotective properties.[1][2]

Research interest in the humanin peptide has grown substantially since its discovery, with preclinical studies investigating its roles in neuroprotection, metabolic regulation, cellular stress resistance, and aging biology. Humanin circulates endogenously in human plasma, and levels appear to decline with age — a pattern that has driven investigation into its potential relevance to age-related pathology.[3]

Compound Profile

What Does Humanin Actually Do?

Humanin research suggests it functions as a broad-spectrum cytoprotective peptide. In preclinical models, it has demonstrated the ability to protect cells from apoptosis triggered by diverse insults including amyloid-beta toxicity, oxidative stress, serum deprivation, and ischemia-reperfusion injury.[1][4] The scope of its protective effects across multiple tissues and stress types is unusual for a peptide of its size.

Circulating humanin levels in humans have been correlated inversely with age and positively with mitochondrial function markers. Centenarian populations and their offspring tend to show higher circulating humanin levels compared to age-matched controls, though whether this reflects cause or consequence of longevity remains unclear.[3]

How Humanin Works

Humanin appears to exert cytoprotection through multiple receptor-mediated and intracellular signalling pathways. Extracellularly, humanin binds the formyl peptide receptor-like 1 (FPRL1/FPR2), a G protein-coupled receptor expressed in neurons and immune cells. Structural studies have revealed the molecular basis of this interaction, showing humanin competes with amyloid-beta for FPR2 binding.[5]

Intracellularly, humanin interacts directly with pro-apoptotic proteins including Bax and BID, preventing their translocation to the mitochondrial membrane and thereby inhibiting the intrinsic apoptosis cascade. Humanin also binds IGFBP-3, modulating IGF-1 signalling and influencing metabolic pathways involved in glucose homeostasis and insulin sensitivity.[3]

The STAT3 signalling axis appears to mediate many of humanin’s downstream effects. Humanin activates STAT3 phosphorylation through a trimeric receptor complex composed of CNTFR, WSX-1, and gp130, linking mitochondrial peptide signalling to classical cytokine receptor pathways.

Longevity / Healthy Aging Context

Humanin’s position as a mitochondrial-derived peptide that declines with age has made it a focus of longevity and healthy aging research. The observation that centenarians maintain higher circulating humanin levels has generated hypotheses about its role as an endogenous protective signal against age-related cellular decline.[3]

Preclinical aging models have shown that humanin administration can attenuate markers of cellular senescence and oxidative damage. In rodent studies, humanin treatment improved mitochondrial function in aged tissues and reduced age-associated inflammation. These effects appear consistent with humanin’s role as a retrograde signalling molecule from mitochondria to the nucleus.[4]

However, the causal relationship between humanin levels and aging outcomes remains unestablished in humans. While correlational data from centenarian studies is suggestive, interventional clinical trials have not yet been conducted. The evidence confidence for longevity applications remains preclinical. Compare with Epithalon and MOTS-c for related longevity-focused peptide profiles, or see the broader Longevity / Healthy Aging goal page.

Recovery & Sleep Context

Humanin’s cytoprotective effects extend to tissue recovery contexts, with preclinical evidence suggesting it may support cellular resilience under stress conditions relevant to recovery and sleep research. Its anti-apoptotic mechanism — blocking Bax translocation and caspase activation — is relevant to tissue repair processes where programmed cell death can impair recovery.[4]

In cardiac ischemia-reperfusion models, humanin pretreatment reduced infarct size and preserved cardiomyocyte viability, suggesting a role in tissue protection during recovery from ischaemic insults.[6] Similar protective effects have been observed in renal and hepatic injury models, indicating broad tissue applicability.

Research into humanin’s effects on sleep architecture or circadian biology is limited. The recovery context is primarily derived from tissue-level cytoprotection data rather than systemic recovery or sleep quality endpoints. See the Recovery & Sleep goal page for broader context.

Muscle Growth Context

Recent research has identified humanin as a potential modulator of skeletal muscle homeostasis, relevant to muscle growth research contexts. In vitro studies using human skeletal muscle cells have demonstrated that humanin attenuates dexamethasone-induced muscle atrophy, suggesting a role in protecting muscle tissue from glucocorticoid-mediated wasting.[7]

The mechanism appears to involve humanin’s interaction with IGFBP-3 and downstream IGF-1 signalling pathways. By binding IGFBP-3, humanin may increase local IGF-1 bioavailability — a pathway with established relevance to muscle protein synthesis and hypertrophy signalling.[3] This connects humanin to broader anabolic signalling networks studied in peptides like IGF-1 LR3.

However, direct evidence for humanin-mediated muscle hypertrophy in vivo is absent. The current evidence supports an anti-catabolic rather than anabolic role, with the most robust data coming from muscle-wasting prevention models rather than growth promotion paradigms. See the Muscle Growth goal page for related research.

Humanin Benefits

• Broad cytoprotection: Research demonstrates protective effects against apoptosis across neuronal, cardiac, pancreatic, and skeletal muscle cell types — an unusually wide tissue spectrum for a single peptide.[1][4]
• Neuroprotective activity: Originally discovered for protection against amyloid-beta toxicity, humanin has shown neuroprotective effects in multiple neurodegenerative disease models including Alzheimer’s-relevant insults.[1][2][5]
• Metabolic regulation: Preclinical data suggests humanin improves insulin sensitivity and glucose homeostasis through IGFBP-3/IGF-1 axis modulation.[3]
• Anti-inflammatory properties: Humanin reduces inflammatory signalling in multiple tissue contexts, potentially through FPRL1/FPR2-mediated immune modulation.[5]
• Mitochondrial function support: As an endogenous mitochondrial peptide, humanin appears to participate in retrograde mitochondria-to-nucleus signalling that maintains cellular bioenergetic capacity.[8]

Humanin Side Effects

Humanin is an endogenous peptide — produced naturally by human mitochondria — which provides a theoretical safety advantage over synthetic compounds. Preclinical toxicology data across multiple animal studies has not identified significant adverse effects at physiologically relevant concentrations.[4]

Potential considerations from preclinical research include:

• Anti-apoptotic concerns: Humanin’s potent inhibition of programmed cell death raises theoretical questions about effects on normal cellular turnover and tumour surveillance, though no pro-tumorigenic effects have been reported in animal studies.
• Dose-response complexity: Some studies suggest biphasic or non-linear dose-response relationships, where supraphysiological concentrations may not maintain the same effect profile as lower levels.
• Limited human safety data: No formal clinical trials have assessed humanin safety in humans. All safety inferences are derived from preclinical models and observational data on endogenous levels.

Half-Life

Endogenous humanin has a relatively short circulating half-life, estimated at minutes to a few hours in preclinical models. This short duration has driven development of analogue peptides with enhanced stability, most notably [Gly14]-humanin (HNG), which incorporates a single amino acid substitution that increases potency approximately 1,000-fold while extending biological activity.[3]

The pharmacokinetic profile of exogenous humanin has been characterised primarily in rodent models, where intraperitoneal and subcutaneous administration routes have been used. Tissue distribution studies indicate humanin accumulates preferentially in metabolically active organs including brain, heart, and liver.

Limits of Current Evidence

• No human clinical trials: Despite over two decades of research since discovery, humanin has not entered formal clinical development. All efficacy data derives from cell culture and animal models.
• Correlational longevity data: The centenarian humanin level observations are associative, not causal. Higher humanin could be a marker rather than a driver of longevity.
• Analogue complexity: Much of the preclinical literature uses HNG or other analogues rather than native humanin, complicating direct translation.
• Measurement variability: Circulating humanin assays have faced standardisation challenges, with different ELISA platforms yielding variable absolute concentrations.
• Publication bias: As a peptide with an appealing narrative (mitochondrial origin, longevity connection), positive results may be disproportionately published.

Verdict

Humanin is a genuinely novel class of signalling molecule — an endogenous mitochondrial-derived peptide with demonstrated cytoprotective properties across multiple tissue types and stress models. The breadth of preclinical evidence is substantial, and the centenarian correlation data adds biological plausibility to longevity-related hypotheses.

However, the complete absence of human interventional data after 25 years of research is notable. Humanin remains firmly in the preclinical research phase. The evidence supports it as a biologically significant endogenous peptide with therapeutic potential, but translational confidence should remain proportional to the available data — which is extensive in rodents and absent in human trials.

FAQ

What is humanin peptide?

Humanin is a 24-amino acid peptide encoded within the mitochondrial genome. It was discovered in 2001 from surviving neurons in Alzheimer’s disease brain tissue and is classified as a mitochondrial-derived peptide (MDP). Research suggests it functions as a cytoprotective signalling molecule with effects across multiple tissues.

Is humanin the same as MOTS-c?

No. Both humanin and MOTS-c are mitochondrial-derived peptides, but they are encoded by different regions of mitochondrial DNA and have distinct mechanisms. Humanin is primarily studied for cytoprotection and neuroprotection, while MOTS-c research focuses on metabolic regulation and exercise biology.

Why do humanin levels decline with age?

Circulating humanin levels decrease with age, likely reflecting age-related decline in mitochondrial function and mitochondrial DNA copy number. Since humanin is encoded by mitochondrial DNA, reduced mitochondrial biogenesis and increased mitochondrial damage with aging would be expected to reduce humanin production.

What is HNG humanin?

[Gly14]-humanin (HNG) is a synthetic analogue of humanin in which the serine at position 14 is replaced with glycine. This single substitution increases biological potency approximately 1,000-fold compared to native humanin, making HNG the most commonly used humanin variant in preclinical research.

What does humanin research suggest about longevity?

Observational studies have found that centenarians and their offspring tend to have higher circulating humanin levels than age-matched controls. Preclinical studies show humanin can reduce age-related cellular damage markers. However, whether humanin causally influences lifespan or is simply a biomarker of healthy aging remains unestablished.

Has humanin been tested in clinical trials?

As of current evidence, humanin has not entered formal human clinical trials for any therapeutic indication. All efficacy and safety data derives from preclinical models (cell culture and animal studies). The peptide remains in the research phase with no approved clinical applications.

References

1. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proc Natl Acad Sci U S A. 2001. PMID: 11371646
2. Hashimoto Y, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer’s disease-relevant insults. J Neurosci. 2001. PMID: 11717357
3. Hazafa A, et al. Humanin: A mitochondrial-derived peptide in the treatment of apoptosis-related diseases. Life Sci. 2021. PMID: 33130077
4. Zhu S, et al. The Molecular Structure and Role of Humanin in Neural and Skeletal Diseases, and in Tissue Regeneration. Front Cell Dev Biol. 2022. PMID: 35372353
5. Zhu Y, et al. Structural basis of FPR2 in recognition of Aβ42 and neuroprotection by humanin. Nat Commun. 2022. PMID: 35365641
6. Kumfu S, et al. Humanin Exerts Neuroprotection During Cardiac Ischemia-Reperfusion Injury. J Alzheimers Dis. 2018. PMID: 29376862
7. Elhusseiny R, et al. Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells. Physiol Rep. 2026. PMID: 41732124
8. Karachaliou CE, et al. Neuroprotective Action of Humanin and Humanin Analogues: Research Findings and Perspectives. Biology (Basel). 2023. PMID: 38132360